Feature | May 16, 2013

Elixir Gains European Approval for Fully Bioresorbable Drug-Eluting Coronary Stent

Results of the international pivotal DESolve Nx trial to be presented at the late-breaking clinical trials session of EuroPCR 2013

Elixer bioresorbable stent
Elixer bioresorbable stent

May 16, 2013 — Elixir Medical Corp. announced it received CE (Conformité Européenne) mark approval for its DESolve Novolimus-eluting bioresorbable coronary stent scaffold system. The scaffold is designed to degrade in about one year returning the patients’ coronary vessel ultimately to its normal de novo state.

 “The CE mark approval for DESolve brings to the market a differentiated product platform with important advantages,” said Martin Leon, M.D., New York – Presbyterian Hospital/Columbia University Medical Center, New York, N.Y., and chairman of Elixir Medical’s DESolve Scaffold Program. “Elixir’s DESolve may help to transform the interventional treatment of patients with coronary artery disease by providing optimal vessel support when needed and degrading in about a year leaving the vessel free of a permanent metallic implant.”

Results of the international pivotal DESolve Nx trial, designed to enroll 120 patients at 15 centers in Europe, Brazil and New Zealand were submitted as part of the CE mark application, and will be presented in Paris in the Main Arena of the Palais Des Congres de Paris at the “From Late Breaking Trial to Clinical Practice” session of EuroPCR 2013 Tuesday, May 21. The DESolve Nx trial represents one of the largest bioresorbable scaffold clinical trials with QCA (quantitative coronary angiography) follow up in the industry to date.

The primary safety endpoint of the DESolve Nx trial is the composite of major adverse cardiac events (MACE) comprised of cardiac death, target vessel myocardial infarction (MI) and clinically indicated target vessel revascularization (TLR). The primary angiographic endpoint of the trial is in-scaffold late lumen loss at 6 months as assessed by QCA (quantitative coronary angiography). In a sub-set of patients, additional QCA assessment will be conducted at 24 months; scaffold and vessel assessment using intravascular ultrasound (IVUS), optical coherent tomography (OCT) will be also conducted at baseline, six and 24 months; computed tomography will also be conducted at 12 months, providing long-term assessment of the scaffold.

“The CE mark for DESolve is a major milestone that confirms the impressive results of the device performance observed in the clinical setting,” said Stefan Verheye, M.D., Ph.D., ZNA Middleheim Hospital, Antwerp, Belgium, and co-principal investigator of the DESolve Nx study. “Having used the DESolve bioresorbable scaffold system in the first-in-man study and observed its outstanding performance in the clinic during the subsequent DESolve Nx pivotal trial, I am confident that Elixir’s fully bioresorbable DESolve system is poised to lead the next frontier of interventional cardiology innovation.”

“The CE mark approval of Elixir’s DESolve represents a major achievement in interventional cardiology as it brings together important performance characteristics that physicians are seeking for the better treatment of their patients,” said Alexandre Abizaid, M.D., Ph.D., Instituto Dante Pazzanese de Cardiologia in Sao Paulo, Brazil, and co-principal investigator of the DESolve Nx trial. “DESolve’s unique characteristics include its ability to maintain radial strength and vessel support for the critical period of vessel healing, the ability to self-appose to the nominal vessel wall, its excellent scaffold expansion range, and its ability to degrade in the body in about a year.”

The approval fulfills a goal by the maker to offer a comprehensive product portfolio of three CE mark approved drug-eluting systems spanning all coronary stent market segments – including a novolimus-eluting metal stents with both biodegradable polymer and durable polymer, and now a bioresorbable stent.

Elixir intends to initiate commercial sales of DESolve in a broad range of sizes in select international markets later this year.

The DESolve scaffold, developed from a proprietary and proven poly-L lactide (PLLA)-based polymer, provides optimal strength and support to the artery while delivering the novel anti-proliferative drug, novolimus. The unique attributes of the DESolve scaffold system include (a) its ability to self-appose to the nominal vessel wall size in cases of malapposition; (b) its ability to maintain radial strength and vessel support for the necessary period of vessel healing while degrading in about a year; and (c) its ability to have a wide margin of expansion.

For more information www.elixirmedical.com

 

Related Content

DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Overlay Init